Drug Trial Radar · NCT06928272
Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study
Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
348
Planned (sponsor's estimate)
Start
Sep 10, 2025
Primary completion
Dec 2026
Study completion Dec 2027
Sponsor
- Lead sponsor
- Douglas D. FraserAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Long-Covid (LC)-Revitalize clinical study is testing repurposed drug treatments for Long Covid, involving adult participants from Brazil, Canada, Italy, South Africa, Uganda, the United States, and Zambia. To qualify, participants must have had Covid-19 and experienced Long Covid symptoms for at least three months. The main goal of the study is to determine whether the drug treatments can improve symptoms in five key areas: 1) fatigue, 2) breathing, 3) memory, thinking, and communication, 4) muscle and joint pain, and 5) circulation. A secondary goal is to assess changes in the body, such as reducing inflammation, as well as to confirm the safety and tolerability of the treatments. In the first phase, 348 participants will take either one of two existing medications (upadacitinib or pirfenidone) or a placebo (a pill with no active ingredient) for three months. Although these medications are not yet approved for Long Covid, they are authorized for use in treating other health conditions. This study is adaptive, meaning it may adjust based on early results. In the second phase, the study could continue testing the most effective drug(s) against a placebo with new participants, explore combinations of drugs to see if they improve results, or discontinue the drugs if they prove ineffective or unsafe and test alternative treatments.
Conditions
- Long COVID
Interventions
PirfenidoneDrug
Initial dose titration: First week (days 1-7): 1 capsule (267 mg), 3 times daily (801 mg/day) Second week (days 8-14): 2 capsules (534 mg), 3 times daily (1602 mg/day) Maintenance dose: Third week and thereafter (days 15+): 3 capsules (801 mg), 3 times daily (2403 mg/day)
Placebo for pirfenidoneDrug
First week (days 1-7): 1 capsule, 3 times daily Second week (days 8-14): 2 capsules, 3 times daily Third week and thereafter (days 15+): 3 capsules, 3 times daily
UpadacitinibDrug
1 capsule (15 mg), once daily for 3 months
Placebo for upadacitinibDrug
1 capsule, once daily for 3 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Symptom Burden Questionnaire (SBQ) SubscalesTime frame: The Phase 1 time frame is from enrollment on Day 1 through to the end of follow-up at Month 6, and the Phase 2 time frame will be determined based on the results of Phase 1.
Locations
10 sites in 7 countries. Site status is shown where the registry gives one.
Laura Rodriguez Research Institute
San Diego, California · Recruiting
Ini-Fiocruz
Rio de Janeiro, Rio de Janerio, Brazil · Recruiting
Institut de Recherches Cliniques de Montréal (IRCM)
Montreal, Quebec, Canada · Recruiting
Centre de Recherche du CHUS (CRCHUS)
Sherbrooke, Quebec, Canada · Recruiting
Università degli Studi di Modena e Reggio Emilia
Modena, Italy · Not yet recruiting
INMI Lazzaro Spallanzani IRCCS
Roma, Roma, Italy · Not yet recruiting
Sapienza Università di Roma
Roma, Roma, Italy · Not yet recruiting
Family Centre for Research with Ubuntu (FAMCRU), Stellenbosch University
Cape Town, Western Cape, South Africa · Not yet recruiting
Joint Clinical Research Centre (JCRC)
Kampala, Kampala, Uganda · Not yet recruiting
University Teaching Hospital
Lusaka, Lusaka Province, Zambia · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.